NFE2L2 and neoplasm: Kobayashi et al. showed that the simultaneous inhibition of CD44v9 and Nrf2 may elevate ROS levels, thereby inhibiting tumour progression and increasing the efficacy of chemotherapy through oxidative stress [132].